|
|
Molecular markers and pathogenically targeted
therapy in non-small cell lung cancer |
Bo PENG BA 1, Jinnong ZHANG MD 2, Jamile S. WOODS MD 3, Wei PENG MD, PhD 3, 4, |
1.College of Arts and Sciences,
University of Pennsylvania, Philadelphia, PA 19104, USA; 2.Pulmonary Division of
Union Hospital, Huazhong University of Science and Technology, Wuhan
430022, China; 3.Department of Pulmonary
and Critical Care Medicine, Salt Lake Regional Medical Center, Iasis
Healthcare, UT 84102, USA; 4.2009-10-29 14:44:41; |
|
|
Abstract Lung cancer is one of the most common human cancers and the number one cancer killer in the United States. In general, lung cancer includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), but NSCLC accounts for approximately 90% of lung cancer. The early diagnosis and therapy of lung cancer still presents a big challenge because validated screening tools, which can improve current early detection to reduce mortality from lung cancer, do not exist. Over the last decade, molecular genetic abnormalities have been described in NSCLC, including chromosomal aberrations, overexpression of oncogenes, and deletion and/or mutations in tumor suppressor genes. These molecular markers in NSCLC demonstrated close associations with the development of lung cancer such as Ras, the epidermal growth factor receptor (EGFR, or c-erbB-1), HER2 (c-erbB-2), c-Met, and Bcl-2. Therefore, this information may be applied for early cancer detection, classification, novel targeted therapy, and prognosis in NSCLC. Recent clinical data have revealed that targeted therapy might be the second-line therapy as an alternative approach. Currently, the targeted therapies are mainly focused on two lung cancer pathways, the EGFR and the vascular endothelial growth factor (VEGF) pathways. Some clinical trials are very encouraging, but some of them are not. However, these trials have not identified a subgroup of NSCLC with biomarkers. Therefore, it is very important to select NSCLC patients with biomarkers to match targeted agents so that we can further identify effectiveness of targeted therapy in the future.
|
Keywords
lung cancer
carcinoma, non-small cell lung cancer
molecular markers
targeted therapy
|
Issue Date: 05 September 2009
|
|
|
Parkin D M, Bray F, Ferlay J, Pisani P. Globalcancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74―108
doi: 10.3322/canjclin.55.2.74
|
|
Alberg A J, Samet J M. Epidemiology of lung cancer. Chest, 2003, 123: 21S
doi: 10.1378/chest.123.1_suppl.21S
|
|
Zang E A, Wynder E L. Differences in lung cancerrisk between men and women: examination of the evidence. J Natl Cancer Inst, 1996, 88(34): 183―192
doi: 10.1093/jnci/88.3-4.183
|
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun M J. Cancer statistics, 2008. CA Cancer J Clin, 2008, 58(2): 71―96
doi: 10.3322/CA.2007.0010
|
|
Molina J R, Adjei A A, Jett J R. Advances in chemotherapy of non-small cell lung cancer. Chest, 2006, 130(4): 1211―1219
doi: 10.1378/chest.130.4.1211
|
|
Mariadason J M, Augenlicht L H, Arango D. Microarray analysis in the clinical management of cancer. Hematol Oncol Clin North Am, 2003, 17(2): 377―387
doi: 10.1016/S0889-8588(03)00006-6
|
|
Anglim P P, Alonzo T A, Laird-Offringa I A. DNA methylation-based biomarkers forearly detection of non-small cell lung cancer: an update. Mol Cancer, 2008, 7: 81
doi: 10.1186/1476-4598-7-81
|
|
Mountain C F. New prognostic factors in lung cancer. Biologic prophets of cancercell aggression. Chest, 1995, 108(1): 246―254
doi: 10.1378/chest.108.1.246
|
|
Salgia R, Skarin A T. Molecular abnormalities inlung cancer. J Clin Oncol, 1998, 16(3): 1207―1217
|
|
Strauss G M, Kwiatkowski D J, Harpole D H, Lynch T J, Skarin A T, Sugarbaker D J. Molecular and pathologic markers in stage I non-small cell carcinomaof the lung. J Clin Oncol, 1995, 13(5): 1265―1279
|
|
Rosell R, Felip E, Garcia-Campelo R, Balana C. Thebiology of non-small-cell lung cancer: identifying new targets forrational therapy. Lung Cancer, 2004, 46(2): 135―148
doi: 10.1016/j.lungcan.2004.04.031
|
|
Devereux T R, Taylor J A, Barrett J C. Molecular mechanisms of lung cancer. Interaction of environmentaland genetic factors. Giles F. Filley Lecture.Chest, 1996, 109(3 Suppl): 14S―19S
doi: 10.1378/chest.109.3_Supplement.14S
|
|
Killary A M, Wolf M E, Giambernardi T A, Naylor S L. Definition of a tumor suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci USA, 1992, 89(22): 10877―10881
doi: 10.1073/pnas.89.22.10877
|
|
Otterson G, Lin A, Kay F. Genetic etiology of lung cancer. Oncology (Huntingt), 1992, 6(9): 97―104, 107; discussion 108,111―112
|
|
Hirao T, Nelson H H, Ashok T D, Wain J C, Mark E J, Christiani D C, Wiencke J K, Kelsey K T. Tobacco smoke-induced DNA damage and an early age ofsmoking initiation induce chromosome loss at 3p21 in lung cancer. Cancer Res, 2001, 61(2): 612―615
|
|
Hibi, K, Takahashi, T, Yamakawa, K, Ueda R, Sekido Y, Ariyoshi Y, Suyama M, Takagi H, Nakamura Y, Takahashi T. Three distinct regions involvedin 3p deletion in human lung cancer. Oncogene, 1992, 7: 445―449
|
|
Hibi K, Takahashi T, Yamakawa K, Ueda R, Sekido Y, Ariyoshi Y, Suyama M, Takagi H, Nakamura Y, Takahashi T. Deletion mapping of the shortarm of chromosome 8 in non-small cell lung carcinoma. Genes Chromosomes Cancer, 1993, 7(3): 85―88
|
|
Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K. Genetic susceptibility tosquamous cell carcinoma of the lung in relation to cigarette smokingdose. Cancer Res, 1991, 51(19): 5177―5180
|
|
Ambrosone C B, Rao U, Michalek A M, Cummings K M, Mettlin C J. Lung cancer histologic typesand family history of cancer. Analysis of histologic subtypes of 872patients with primary lung cancer. Cancer, 1993, 72(4): 1192―1198
doi: 10.1002/1097-0142(19930815)72:4<1192::AID-CNCR2820720410>3.0.CO;2-S
|
|
Slebos R J, Kibbelaar R E, Dalesio O, Kooistra A, Stam J, Meijer C J, Wagenaar S S, Vanderschueren RG, van Zandwijk N, Mooi W J. K-ras oncogene activation as a prognostic marker in adenocarcinomaof the lung. N Engl J Med, 1990, 323(9): 561―565
|
|
Rodenhuis S, Slebos R J. Clinical significance ofras oncogene activation in human lung cancer. Cancer Res, 1992, 52(Suppl): 2665―2669
|
|
Graziano S L, Gamble G P, Newman N B, Abbott L Z, Rooney M, Mookherjee S, Lamb M L, Kohman L J, Poiesz B J. Prognostic significance of K-ras codon 12 mutations in patients withresected stage I and II non-small-cell lung cancer. J Clin Oncol, 1999, 17(2): 668―675
|
|
Graziano S L, Gamble G P, Newman N B, Abbott L Z, Rooney M, Mookherjee S, Lamb M L, Kohman L J, Poiesz B J. Cigarette smoking is strongly associated with mutation of the k-rasgene in patients with primary adenocarcinomaof the lung. Cancer, 2001, 92(6): 1525―1530
doi: 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H
|
|
Velu T J, Beguinot L, Vass W C, Willingham M C, Merlino G T, Pastan I, Lowy D R. Epidermal-growth-factor-dependenttransformation by a human EGF receptor proto-oncogene. Science, 1987, 238(4832): 1408―1410
doi: 10.1126/science.3500513
|
|
To C T, Tsao M S. The roles of hepatocyte growthfactor/scatter factor and met receptor in human cancers (Review). Oncol Rep, 1998, 5(5): 1013―1024
|
|
Ichimura, E, Maeshima, A, Nakajima, T, Nakamura, T. Expressionof c-met/HGF receptor in human non-small cell lung carcinomas in vitroand in vivo and its prognostic significance. Jpn J Cancer Res, 1996, 87(10): 1063―1069
|
|
Hockenbery D, Nuñez G, Milliman C, Schreiber R D, Korsmeyer S J. Bcl-2 is an inner mitochondrialmembrane protein that blocks programmed cell death. Nature, 1990, 348(6299): 334―336
doi: 10.1038/348334a0
|
|
Anton R C, Brown R W, Younes M, Gondo M M, Stephenson M A, Cagle P T. Absence of prognostic significance of bcl-2 immunopositivityin non-small cell lung cancer: analysis of 427 cases. Hum Pathol, 1997, 28(9): 1079―1082
doi: 10.1016/S0046-8177(97)90062-9
|
|
Ohmura Y, Aoe M, Andou A, Shimizu N. Telomeraseactivity and Bcl-2 expression in non-small cell lung cancer. Clin Cancer Res, 2000, 6(8): 2980―2987
|
|
Laudanski J, Chyczewski L, Niklinska W E, Kretowska M, Furman M, Sawicki B, Niklinski J. Expressionof bcl-2 protein in non-small cell lung cancer: correlation with clinicopathologyand patient survival. Neoplasma, 1999, 46(1): 25―30
|
|
Groeger A M, Caputi M, Esposito V, De Luca A, Salat A, Murabito M, Giordano G G, Baldi F, Giordano A, Wolner E. Bcl-2protein expression correlates with nodal status in non small celllung cancer. Anticancer Res, 1999, 19(1B): 821―824
|
|
Pezzella F, Turley H, Kuzu I, Tungekar M F, Dunnill M S, Pierce C B, Harris A, Gatter K C, Mason D Y. bcl-2 protein in non-small cell lung carcinoma. N Engl J Med, 1993, 329(10): 690―694
doi: 10.1056/NEJM199309023291003
|
|
Silvestrini R, Costa A, Lequaglie C, Mochen C, Veneroni S, Leutner M, Ravasi G. Bcl-2protein and prognosis in patients with potentially curable non-small-celllung cancer. Virchows Arch, 1998, 432(5): 441―444
doi: 10.1007/s004280050188
|
|
Huang C I, Neuberg D, Johnson B E, Wei J Y, Christiani D C. Expression of bcl-2 proteinis associated with shorter survival in nonsmall cell lung carcinoma. Cancer, 2003, 98(1): 135―143
doi: 10.1002/cncr.11461
|
|
Sharp T V, Munoz F, Bourboulia D, Presneau N, Darai E, Wang H W, Cannon M, Butcher D N, Nicholson A G, Klein G, Imreh S, Boshoff C. LIMdomains-containing protein 1 (LIMD1), a tumor suppressor encoded atchromosome 3p21.3, binds pRB and represses E2F-driven transcription. Proc Natl Acad Sci USA, 2004, 101(47): 16531―16536
doi: 10.1073/pnas.0407123101
|
|
Zhang S Y, Liu S C, Johnson D G, Klein-Szanto A J. E2F-1 gene transfer enhances invasiveness of human head and neckcarcinoma cell lines. Cancer Res, 2000, 60(21): 5972―5976
|
|
Banerjee D, Gorlick R, Liefshitz A, Danenberg K, Danenberg P C, Danenberg P V, Klimstra D, Jhanwar S, Cordon-Cardo C, Fong Y, Kemeny N, Bertino J R. Levels of E2F-1 expression are higher in lung metastasis of coloncancer as compared with hepatic metastasis and correlate with levelsof thymidylate synthase. Cancer Res, 2000, 60(9): 2365―2367
|
|
Lane D P. Cancer. p53, guardian of the genome. Nature, 1992, 358(6381): 15―16
doi: 10.1038/358015a0
|
|
Tsao M S, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu C Q, Livingston R, Johnson D H, Rigas J, Seymour L, Winton T, Shepherd F A. Prognostic and predictive importance of p53 and RAS foradjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol, 2007, 25(33): 5240―5247
doi: 10.1200/JCO.2007.12.6953
|
|
Knudson A G Jr. The ninth Gordon Hamilton-Fairley memorial lecture. Hereditary cancers:clues to mechanisms of carcinogenesis. Br J Cancer, 1989, 59(5): 661―666
|
|
Xu H J, Quinlan D C, Davidson A G, Hu S X, Summers C L, Li J, Benedict W F. Altered retinoblastoma proteinexpression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst, 1994, 86(9): 695―699
doi: 10.1093/jnci/86.9.695
|
|
Xu H J, Cagle P T, Hu S X, Li J, Benedict W F. Altered retinoblastoma andp53 protein status in non-small cell carcinoma of the lung: potentialsynergistic effects on prognosis. ClinCancer Res, 1996, 2(7): 1169―1176
|
|
Shapiro G I, Rollins B J. p16INK4A as a human tumorsuppressor. Biochim Biophys Acta, 1996, 18; 1242(3): 165―169
|
|
Hannon G J, Beach D. p15INK4B is a potential effectorof TGF-beta-induced cell cycle arrest. Nature, 1994, 371(6494): 257―261
doi: 10.1038/371257a0
|
|
Shapiro G I, Edwards C D, Kobzik L, Godleski J, Richards W, Sugarbaker D J, Rollins B J. Reciprocal Rb inactivation and p16INK4 expression in primary lungcancers and cell lines. Cancer Res, 1995, 55(3): 505―509
|
|
Kratzke R A, Greatens T M, Rubins J B, Maddaus M A, Niewoehner D E, Niehans G A, Geradts J. Rband p16INK4a expression in resected non-small cell lung tumors. Cancer Res, 1996, 56(15): 3415―3420
|
|
Gonzalez-Quevedo R, Iniesta P, Moran A, de Juan C, Sanchez-Pernaute A, Fernandez C, Torres A, Diaz-Rubio E, Balibrea J L, Benito M. Cooperativerole of telomerase activity and p16 expression in the prognosis ofnon-small-cell lung cancer. J Clin Oncol, 2002, 20(1): 254―262
doi: 10.1200/JCO.20.1.254
|
|
Gautam A, Li Z R, Bepler G. RRM1-induced metastasis suppression through PTEN-regulatedpathways. Oncogene, 2003, 22(14): 2135―2142
doi: 10.1038/sj.onc.1206232
|
|
Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNAsynthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med, 2007, 356(8): 800―808
doi: 10.1056/NEJMoa065411
|
|
Ohta Y, Nozaki Z, Nozawa H, Kamesui T, Tsunezuka Y, Oda M, Watanabe G. Thepredictive value of vascular endothelial growth factor and nm23 forthe diagnosis of occult metastasis in non-small cell lung cancer. Jpn J Cancer Res, 2001, 92(3): 361―366
|
|
Tomita M, Ayabe T, Matsuzaki Y, Onitsuka T. Immunohistochemicalanalysis of nm23-H1 gene product in node-positive lung cancer andlymph nodes. Lung Cancer, 1999, 24(1): 11―16
doi: 10.1016/S0169-5002(99)00018-5
|
|
Higashiyama M, Taki T, Ieki Y, Adachi M, Huang C L, Koh T, Kodama K, Doi O, Miyake M. Reduced motility related protein-1 (MRP-1/CD9) gene expressionas a factor of poor prognosis in non-small cell lung cancer. Cancer Res, 1995, 55(24): 6040―6044
|
|
Lau L F, Lam S C. The CCN family of angiogenicregulators: the integrin connection. ExpCell Res, 1999, 248(1): 44―57
doi: 10.1006/excr.1999.4456
|
|
Chen N, Leu S J, Todorovic V, Lam S C, Lau L F. Identification of a novel integrin alphavbeta3binding site in CCN1 (CYR61) critical for pro-angiogenic activitiesin vascular endothelial cells. J Biol Chem, 2004, 279(42): 44166―44176
doi: 10.1074/jbc.M406813200
|
|
Xie D, Yin D, Wang H J, Liu G T, Elashoff R, Black K, Koeffler H P. Levels of expression of CYR61and CTGF are prognostic for tumor progression and survival of individualswith gliomas. Clin Cancer Res, 2004, 10(6): 2072―2081
doi: 10.1158/1078-0432.CCR-0659-03
|
|
Chen C C, Chen N, Lau L F. The angiogenic factors Cyr61 and connective tissue growthfactor induce adhesive signaling in primary human skin fibroblasts. J Biol Chem, 2001, 276(13): 10443―10452
doi: 10.1074/jbc.M008087200
|
|
Tong X, Xie D, O'Kelly J, Miller C W, Muller-Tidow C, Koeffler H P. Cyr61, a member of CCN family, is a tumor suppressorin non-small cell lung cancer. J Biol Chem, 2001, 276(50): 47709―47714
doi: 10.1074/jbc.M107878200
|
|
Chang C C, Shih J Y, Jeng Y M, Su J L, Lin B Z, Chen S T, Chau Y P, Yang P C, Kuo M L. Connectivetissue growth factor and its role in lung adenocarcinoma invasionand metastasis. J Natl Cancer Inst, 2004, 96(5): 364―375
|
|
Shih J Y, Yang S C, Hong T M, Yuan A, Chen J J, Yu C J, Chang Y L, Lee Y C, Peck K, Wu C W, Yang P C. Collapsin response mediator protein-1 and the invasion and metastasisof cancer cells. J Natl Cancer Inst, 2001, 93(18): 1392―1400
doi: 10.1093/jnci/93.18.1392
|
|
Pérez-Soler R, Chachoua A, Hammond L A, Rowinsky E K, Huberman M, Karp D, Rigas J, Clark G M, Santabárbara P, Bonomi P. Determinants of tumor responseand survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol, 2004, 22(16), 3238―3247
doi: 10.1200/JCO.2004.11.057
|
|
Jackman D M, Yeap B Y, Lindeman N I, Fidias P, Rabin M S, Temel J, Skarin A T, Meyerson M, Holmes A J, Borras A M, Freidlin B, Ostler P A, Lucca J, Lynch T J, Johnson B E, Jänne P A. Phase II clinical trial ofchemotherapy-naive patients>or= 70 years of age treated with erlotinibfor advanced non-small-cell lung cancer. J Clin Oncol, 2007, 25(7): 760―766
doi: 10.1200/JCO.2006.07.5754
|
|
Shepherd F A, Rodrigues Pereira J, Ciuleanu T, Tan E H, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; NationalCancer Institute of Canada Clinical Trials Group. Erlotinib in previouslytreated non-small-cell lung cancer. N EnglJ Med, 2005, 353(2): 123―132
doi: 10.1056/NEJMoa050753
|
|
Herbst R S, Prager D, Hermann R, Fehrenbacher L, Johnson B E, Sandler A, Kris M G, Tran H T, Klein P, Li X, Ramies D, Johnson D H, Miller V A; TRIBUTE Investigator Group.TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combinedwith carboplatin and paclitaxel chemotherapy in advanced non-small-celllung cancer. J Clin Oncol, 2005, 23(25): 5892―5899
doi: 10.1200/JCO.2005.02.840
|
|
Gatzemeier U, Pluzanska A, Szczesna Aet al. Results of a phase III trial of erlotinib(OSI-774) combined with cisplatin and GC chemotherapy in advancednon-small cell lung cancer (NSCLC). J ClinOncol, 2004, 22(suppl 14): 619s
|
|
Giaccone G, Herbst R S, Manegold C, Scagliotti G, Rosell R, Miller V, Natale R B, Schiller J H, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs J S, Averbuch S D, Wolf M K, Rennie P, Fandi A, Johnson D H. Gefitinib in combination with gemcitabine and cisplatinin advanced non-small-cell lung cancer: a phase III trial--INTACT1. J Clin Oncol, 2004, 22(5): 777―784
doi: 10.1200/JCO.2004.08.001
|
|
Herbst R S, Giaccone G, Schiller J H, Natale R B, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves J A, Wolf M K, Krebs A D, Averbuch S D, Ochs J S, Grous J, Fandi A, Johnson D H. Gefitinib in combination with paclitaxeland carboplatin in advanced non-small-cell lung cancer: A phase IIItrial–INTACT 2. J Clin Oncol, 2004, 22(5): 785―794
doi: 10.1200/JCO.2004.07.215
|
|
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong R P, Baselga J. Multi-institutional randomized Phase II trial of gefitinibfor previously treated patients with advanced nonsmall-cell lung cancer(The IDEAL 1 Trial) [corrected]. J ClinOncol, 2003, 21(12): 2237―2246
doi: 10.1200/JCO.2003.10.038
|
|
Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan E H, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportivecare in previously treated patients with refractory advanced non-small-celllung cancer: results from a randomized, placebo-controlled, multicentrestudy (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366(6496): 1527―1537
doi: 10.1016/S0140-6736(05)67625-8
|
|
Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne P A, Bonomi P. Phase II trial of cetuximabin patients with previously treated non-small-cell lung cancer. J Clin Oncol, 2006, 24(33): 5253―5258
doi: 10.1200/JCO.2006.08.2263
|
|
Pirker R, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Park K, Gatzemeier U, Bajeta E, Emig M, Pereira J R. A randomized, multicenter, phase III study of cetuximab in combinationwith cisplatin/vinorelbine (CV) versus CV alone in the first-linetreatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Suppl), 2008, 26(15S): 3
|
|
Socinski M A. Antibodies to the epidermal growth factor receptor in non–smallcell lung cancer: current status of matuzumab and panitumumab. Clinical Cancer Research, 2007, (13): 4597s―4601s
doi: 10.1158/1078-0432.CCR-07-0335
|
|
Sandler A, Gray R, Perry M C, Brahmer J, Schiller J H, Dowlati A, Lilenbaum R, Johnson D H. Paclitaxel-carboplatin aloneor with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355(24): 2542―2550
doi: 10.1056/NEJMoa061884
|
|
Johnson D H, Fehrenbacher L, Novotny W F, Herbst R S, Nemunaitis J J, Jablons D M, Langer C J, DeVore R F 3rd, Gaudreault J, Damico L A, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab pluscarboplatin and paclitaxel with carboplatin and paclitaxel alone inpreviously untreated locally advanced or metastatic non-small-celllung cancer. J Clin Oncol, 2004, 22(11): 2184―2191
doi: 10.1200/JCO.2004.11.022
|
|
Socinski M A, Novello S, Sanchez J M. Efficacy and safety of sunitinib in previously treated,advanced non-small cell lung cancer (NSCLC): Preliminary results ofa multicenter phase II trial. J Clin Oncol, 2006, 24(18S): 7001
|
|
Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Prognostic value of c-erbB-2protein expression in human lung adenocarcinoma and squamous cellcarcinoma. Eur J Cancer, 1991, 27(11): 1372―1375
|
|
Shi D, He G, Cao S, Pan W, Zhang H Z, Yu D, Hung M C. Overexpression of the c-erbB-2/neu-encodedp185 protein in primary lung cancer. MolCarcinog, 1992, 5(3): 213―218
doi: 10.1002/mc.2940050308
|
|
Harpole D H Jr, Herndon J E 2nd, Wolfe W G, Iglehart J D, Marks J R. A prognostic model of recurrenceand death in stage I non-small cell lung cancer utilizing presentation,histopathology, and oncoprotein expression. Cancer Res, 1995, 55(1): 51―56
|
|
Hsieh C C, Chow K C, Fahn H J, Tsai C M, Li W Y, Huang M H, Wang L S. Prognostic significance ofHER-2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg, 1998, 66(4): 1159―1163
doi: 10.1016/S0003-4975(98)00792-9
|
|
Cantero R, Torres A J, Maestro M L, Hernando F, Sanz M T, Del Barco V, Gomez A, Fernandez C, Balibrea J L. Prognostic value of the quantified expression of p185 in non-smallcell lung cancer. J Thorac Cardiovasc Surg, 2000, 119(6): 1119―1125
doi: 10.1067/mtc.2000.105211
|
|
Ardizzoni A, Cafferata M A, Paganuzzi M, Filiberti R, Marroni P, Neri M, Fontana V, Nicolo G, Perdelli L, Stampino C G, Rosso R, Puntoni R. Study of pretreatment serum levels of HER-2/neu oncoproteinas a prognostic and predictive factor in patients with advanced nonsmallcell lung carcinoma. Cancer, 2001, 92(7): 1896―1904
doi: 10.1002/1097-0142(20011001)92:7<1896::AID-CNCR1707>3.0.CO;2-0
|
|
Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E-cadherin and beta-catenin in human non-smallcell lung cancer and the clinical significance. Clin Cancer Res, 2000, 6(12): 4789―4796
|
|
Hommura F, Furuuchi K, Yamazaki K, Ogura S, Kinoshita I, Shimizu M, Moriuchi T, Katoh H, Nishimura M, Dosaka-Akita H. Increased expression of beta-cateninpredicts better prognosis in nonsmall cell lung carcinomas. Cancer, 2002, 94(3): 752―758
doi: 10.1002/cncr.10213
|
|
Bremnes R M, Veve R, Gabrielson E, Hirsch F R, Baron A, Bemis L, Gemmill R M, Drabkin H A, Franklin W A. High-throughput tissue microarray analysis used to evaluatebiology and prognostic significance of the E-cadherin pathway in non-small-celllung cancer. J Clin Oncol, 2002, 20(10): 2417―2428
doi: 10.1200/JCO.2002.08.159
|
|
Burbee D G, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar A F, Lerman M I, Zabarovsky E, White M, Minna J D. Epigenetic inactivation of RASSF1A inlung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst, 2001, 93(9): 691―699
doi: 10.1093/jnci/93.9.691
|
|
Dammann R, Li C, Yoon J H, Chin P L, Bates S, Pfeifer G P. Epigenetic inactivation of a RAS association domain family proteinfrom the lung tumour suppressor locus 3p21.3. Nat Genet, 2000, 25(3): 315―319
doi: 10.1038/77083
|
|
Maruyama R, Sugio K, Yoshino I, Maehara Y, Gazdar A F. Hypermethylation of FHITas a prognostic marker in nonsmall cell lung carcinoma. Cancer, 2004, 100(7): 1472―1477
doi: 10.1002/cncr.20144
|
|
Huncharek M, Muscat J, Geschwind J F. K-ras oncogene mutation as a prognostic marker in non-smallcell lung cancer: a combined analysis of 881 cases. Carcinogenesis, 1999, 20: 1507―1510
doi: 10.1093/carcin/20.8.1507
|
|
Higashiyama M, Kodama K, Yokouchi H, Takami K, Adachi M, Taki T, Ishiguro S, Nakamori S, Yoshie O, Miyake M. KAI1/CD82expression in nonsmall cell lung carcinoma is a novel, favorable prognosticfactor: an immunohistochemical analysis. Cancer, 1998, 83(3): 466―474
doi: 10.1002/(SICI)1097-0142(19980801)83:3<466::AID-CNCR15>3.0.CO;2-U
|
|
Takaoka A, Hinoda Y, Satoh S, Adachi Y, Itoh F, Adachi M, Imai K. Suppressionof invasive properties of colon cancer cells by a metastasis suppressorKAI1 gene. Oncogene, 1998, 16(11): 1443―1453
doi: 10.1038/sj.onc.1201648
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|